Skip to main content
SpringerLink
Log in

Favorable effects of early tolvaptan administration in very elderly patients after repeat hospitalizations for acute decompensated heart failure

  • Original Article
  • Published:
Heart and Vessels Aims and scope Submit manuscript

Abstract

Tolvaptan (TLV) is an oral selective vasopressin 2 receptor antagonist that acts on the distal nephrons, causing a loss of electrolyte-free water. To date, its early administration in very elderly patients after repeat hospitalizations for acute decompensated heart failure (ADHF) despite receiving optimal medical therapy has not been evaluated. Fifty-six ADHF patients who were >80 years old and had been repeatedly hospitalized were retrospectively enrolled in this study. Twenty-five patients (14 men; mean age 86.7 ± 5.3 years; control group) received standard therapy and 31 patients (15 men; mean age 85.5 ± 4.5 years; TLV group) received oral TLV within 24 h of admission. The rate of worsening renal function was significantly lower in the TLV group than in the control group (13 vs. 40%, P < 0.05). The duration of the return to body weight at a steady state was significantly shorter in the TLV group (5.3 ± 2.8 days) than in the control group (13.9 ± 9.2 days, P < 0.01). Consequently, the hospitalization period in the TLV group (13.5 ± 5.9 days) was significantly shorter than that in the control group (24.7 ± 12.3 days, P < 0.01). In conclusion, the early administration of TLV to very elderly patients who underwent repeat hospitalizations for ADHF resulted in immediate decongestion and thus reduced the hospitalization period with a lower incidence of worsening renal function.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

Similar content being viewed by others

References

  1. Sato N, Kajimoto K, Asai K, Mizuno M, Minami Y, Nagashima M, Murai K, Muanakata R, Yumino D, Meguro T, Kawana M, Nejima J, Satoh T, Mizuno K, Tanaka K, Kasanuki H, Takano T, Acute decompensated heart failure syndromes (ATTEND) registry (2010) A prospective observational multicenter cohort study: rationale, design, and preliminary data. Am Heart J 159:949–955

    Article  PubMed  Google Scholar 

  2. Hamaguchi S, Kinugawa S, Tsuchihashi-Makaya M, Goto D, Tsutsui H (2014) Weekend versus weekday hospital admission and outcomes during hospitalization for patients due to worsening heart failure: a report from Japanese Cardiac Registry of Heart Failure in Cardiology (JCARE-CARD). Heart Vessels 29:328–335

    Article  PubMed  Google Scholar 

  3. Kawashiro N, Kasanuki H, Ogawa H, Matsuda N, Hagiwara N, Heart Institute of Japan-Department of Cardiology (HIJC) Investigators (2008) Clinical characteristics and outcome of hospitalized patients with congestive heart failure: results of the HIJC-HF registry. Circ J 72:2015–2020

    Article  PubMed  Google Scholar 

  4. Hamaguchi S, Kinugawa S, Goto D, Tsuchihashi-Makaya M, Yokota T, Yamada S, Yokoshiki H, Takeshita A, JCARE-CARD Investigators (2011) Predictors of long-term adverse outcomes in elderly patients over 80 years hospitalized with heart failure. A report from the Japanese Cardiac Registry of Heart Failure in Cardiology (JCARE-CARD). Circ J 75:2403–2410

    Article  PubMed  Google Scholar 

  5. Yamamura Y, Nakamura S, Itoh S, Hirano T, Onogawa T, Yamashita T, Yamada Y, Tsujimae K, Aoyama M, Kotosai K, Ogawa H, Yamashita H, Kondo K, Tominaga M, Tsujimoto G, Mori T (1998) A highly potent human vasopressin V2-receptor antagonist: pharmacological profile and aquaretic effect by single and multiple oral dosing in rats. J Pharmacol Exp Ther 287:860–867

    CAS  PubMed  Google Scholar 

  6. Gheorghiade M, Niazi I, Ouyang J, Czerwiec F, Kambayashi J, Zampino M, Orlandi C (2003) Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure: results from a double-blind, randomized trial. Circulation 107:2690–2696

    Article  CAS  PubMed  Google Scholar 

  7. Matsue Y, Suzuki M, Seya M, Iwatsuka R, Mizukami A, Nagahori W, Ohno M, Matsumura A, Hashimoto Y (2013) Tolvaptan reduces the risk of worsening renal function in patients with acute decompensated heart failure in high-risk population. J Cardiol 61:169–174

    Article  PubMed  Google Scholar 

  8. Shirakabe A, Hata N, Yamamoto M, Kobayashi N, Shinada T, Tomita K, Tsurumi M, Matsushita M, Okazaki H, Yamamoto Y, Yokoyama S, Asai K, Shimizu W (2014) Immediate administration of tolvaptan prevents the exacerbation of acute kidney injury and improves the mid-term prognosis of patients with severely decompensated acute heart failure. Circ J 78:911–921

    Article  CAS  PubMed  Google Scholar 

  9. Metra M, Nodari S, Parrinello G, Bordonali T, Bugatti S, Danesi R, Fontanella B, Lombardi C, Milani P, Verzura G, Cotter G, Dittrich H, Massie BM, Dei Cas L (2008) Worsening renal function in patients hospitalized for acute heart failure: clinical implications and prognostic significance. Eur J Heart Fail 10:188–195

    Article  PubMed  Google Scholar 

  10. Sarraf M, Masoumi A, Schrier RW (2009) Cardiorenal syndrome in acute decompensated heart failure. Clin J Am Soc Nephrol 4:2013–2026

    Article  CAS  PubMed  Google Scholar 

  11. Chen HH, Redfield MM, Nordstrom LJ, Cataliotti A, Burnett JC, Angiotensin II Jr (2003) AT1 receptor antagonism prevents detrimental renal actions of acute diuretic therapy in human heart failure. Am J Physiol Renal Physiol 284(5):F1115–F1119

    Article  CAS  PubMed  Google Scholar 

  12. Gottlieb SS, Brater DC, Thomas I, Havranek E, Bourge R, Goldman S, Dyer F, Gomez M, Bennett D, Ticho B, Beckman E, Abraham WT (2002) BG9719 (CVT-124), an A1 adenosine receptor antagonist, protects against the decline in renal function observed with diuretic therapy. Circulation 105:1348–1353

    Article  CAS  PubMed  Google Scholar 

  13. Damman K, Valente MA, Voors AA, O’Connor CM, van Veldhuisen DJ, Hillege HL (2014) Renal impairment, worsening renal function, and outcome in patients with heart failure: an updated meta-analysis. Eur Heart J 35:455–469

    Article  PubMed  Google Scholar 

  14. Forman DE, Butler J, Wang Y, Abraham WT, O’Connor CM, Gottlieb SS, Loh E, Massie BM, Rich MW, Stevenson LW, Young JB, Krumholz HM (2004) Incidence, predictors at admission, and impact of worsening renal function among patients hospitalized with heart failure. J Am Coll Cardiol 43:61–67

    Article  PubMed  Google Scholar 

  15. Nieminen MS, Hariola VP (2005) Definition and epidemiology of acute heart failure syndromes. Am J Cardiol 96(6A):5G–10G

    Article  PubMed  Google Scholar 

  16. Ambrosy AP, Pang PS, Khan S, Konstam MA, Fonarow GC, Traver B, Maggioni AP, Cook T, Swedberg K, Burnett JC Jr, Grinfeld L, Udelson JE, Zannad F, Gheorghiade M, EVEREST Trial Investigators (2013) Clinical course and predictive value of congestion during hospitalization in patients admitted for worsening signs and symptoms of heart failure with reduced ejection fraction: findings from the EVEREST trial. Eur Heart J 34:835–843

    Article  PubMed  Google Scholar 

  17. Adams KF Jr, Fonarow GC, Emerman CL, LeJemtel TH, Costanzo MR, Abraham WT, Berkowitz RL, Galvao M, Horton DP (2005) Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE). Am Heart J 149:209–216

    Article  PubMed  Google Scholar 

  18. Ahmed A, Husain A, Love TE, Gambassi G, Dell’Italia LJ, Francis GS, Gheorghiade M, Allman RM, Meleth S, Bourge RC (2006) Heart failure, chronic diuretic use, and increase in mortality and hospitalization: an observational study using propensity score methods. Eur Heart J 27:1431–1439

    Article  PubMed  PubMed Central  Google Scholar 

  19. Ronco C, Cicoira M, McCullough PA (2012) Cardiorenal syndrome type 1: pathophysiological crosstalk leading to combined heart and kidney dysfunction in the setting of acutely decompensated heart failure. J Am Coll Cardiol 60:1031–1042

    Article  PubMed  Google Scholar 

  20. Goldsmith SR, Bart BA, Burnett J (2014) Decongestive therapy and renal function in acute heart failure: time for a new approach? Circ Heart Fail 7:531–535

    Article  PubMed  Google Scholar 

  21. Onogawa T, Sakamoto Y, Nakamura S, Nakayama S, Fujiki H, Yamamura Y (2011) Effects of tolvaptan on systemic and renal hemodynamic function in dogs with congestive heart failure. Cardiovasc Drugs Ther 25(Suppl 1):S67–S76

    Article  PubMed  Google Scholar 

  22. Jujo K, Saito K, Ishida I, Furuki Y, Kim A, Suzuki Y, Sekiguchi H, Yamaguchi J, Ogawa H, Hagiwara N (2016) Randomized pilot trial comparing tolvaptan with furosemide on renal and neurohumoral effects in acute heart failure. ESC Heart Fail 3:177–188

    Article  PubMed  PubMed Central  Google Scholar 

  23. Chen HH, Anstrom KJ, Givertz MM, Stevenson LW, Semigran MJ, Goldsmith SR, Bart BA, Bull DA, Stehlik J, LeWinter MM, Konstam MA, Huggins GS, Rouleau JL, O’Meara E, Tang WH, Starling RC, Butler J, Deswal A, Felker GM, O’Connor CM, Bonita RE, Margulies KB, Cappola TP, Ofili EO, Mann DL, Dávila-Román VG, McNulty SE, Borlaug BA, Velazquez EJ, Lee KL, Shah MR, Hernandez AF, Braunwald E, Redfield MM (2013) Low-dose dopamine or low-dose nesiritide in acute heart failure with renal dysfunction: the ROSE acute heart failure randomized trial. JAMA 310:2533–2543

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Shiba N, Watanabe J, Shinozaki T, Koseki Y, Sakuma M, Kagaya Y, Shirato K, CHART Investigators (2004) Analysis of chronic heart failure registry in the Tohoku district: third year follow-up. Circ J 68:427–434

    Article  PubMed  Google Scholar 

  25. Shiba N, Nochioka K, Miura M, Kohno H, Shimokawa H, CHART-2 Investigators (2011) Trend of westernization of etiology and clinical characteristics of heart failure patients in Japan–first report from the CHART-2 study. Circ J 75:823–833

    Article  PubMed  Google Scholar 

  26. Matsukawa R, Kubota T, Okabe M, Yamamoto Y (2016) Early use of V2 receptor antagonists is associated with a shorter hospital stay and reduction in in-hospital death in patients with decompensated heart failure. Heart Vessels 31:1650–1658

    Article  PubMed  Google Scholar 

  27. Kimura K, Momose T, Hasegawa T, Morita T, Misawa T, Motoki H, Izawa A, Ikeda U (2016) Early administration of tolvaptan preserves renal function in elderly patients with acute decompensated heart failure. J Cardiol 67:399–405

    Article  PubMed  Google Scholar 

  28. Nomura F, Kurobe N, Mori Y, Hikita A, Kawai M, Suwa M, Okutani Y (2008) Multicenter prospective investigation on efficacy, safety of carperitide as a first-line drug for acute heart failure syndrome with preserved blood pressure: COMPASS: carperitide effects observed through monitoring dyspnea in acute decompensated heart failure study. Circ J 72:1777–1786

    Article  CAS  PubMed  Google Scholar 

  29. Hata N, Seino Y, Tsutamoto T, Hiramitsu S, Kaneko N, Yoshikawa T, Yokoyama H, Tanaka K, Mizuno K, Nejima J, Kinoshita M (2008) Effects of carperitide on the long-term prognosis of patients with acute decompensated chronic heart failure: the PROTECT multicenter randomized controlled study. Circ J 72:1787–1793

    Article  CAS  PubMed  Google Scholar 

  30. Izumi K, Eishi K, Yamachika S, Hashizume K, Tada S, Yamane K, Takai H, Tanigawa K, Miura T, Nakaji S (2008) The efficacy of human atrial natriuretic peptide in patients with renal dysfunction undergoing cardiac surgery. Ann Thorac Cardiovasc Surg 14:294–302

    PubMed  Google Scholar 

  31. Suzuki S, Yoshihisa A, Yamaki T, Sugimoto K, Kunii H, Nakazato K, Abe Y, Saito T, Ohwada T, Suzuki H, Saitoh S, Kubota I, Takeishi Y (2013) Acute heart failure volume control multicenter randomized (AVCMA) trial: comparison of tolvaptan and carperitide. J Clin Pharmacol 53:1277–1285

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Suwa M, Seino Y, Nomachi Y, Matsuki S, Funahashi K (2005) Multicenter prospective investigation on efficacy, safety of carperitide for acute heart failure in the “real world” of therapy. Circ J 69:283–290

    Article  PubMed  Google Scholar 

  33. Felker GM, Mentz RJ, Cole RT, Adams KF, Egnaczyk GF, Fiuzat M, Patel CB, Echols M, Khouri MG, Tauras JM, Gupta D, Monds P, Roberts R, O’Connor CM (2017) Efficacy and safety of tolvaptan in patients hospitalized with acute heart failure. J Am Coll Cardiol 69:1399–1406

    Article  CAS  PubMed  Google Scholar 

  34. Dohi K, Ito M (2014) Novel diuretics strategies for the treatment of heart failure in Japan. Circ J 78:1816–1823

    Article  PubMed  Google Scholar 

  35. Matsue Y, Suzuki M, Torii S, Yamaguchi S, Fukamizu S, Ono Y, Fujii H, Kitai T, Nishioka T, Sugi K, Onishi Y, Noda M, Kagiyama N, Satoh Y, Yoshida K, Goldsmith SR (2016) Clinical effectiveness of tolvaptan in patients with acute heart failure and renal dysfunction. J Card Fail 22:423–432

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Cardiology, Ehime Prefectural Central Hospital, 83 Kasuga-machi, Matsuyama, Ehime, 790-0024, Japan

    Masaki Kinoshita, Hideki Okayama, Tetsuya Kosaki, Saki Hosokawa, Go Kawamura, Tatsuya Shigematsu, Tatsunori Takahashi, Yoshitaka Kawada, Go Hiasa, Tadakatsu Yamada, Hiroshi Matsuoka & Yukio Kazatani

Authors
  1. Masaki Kinoshita
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hideki Okayama
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Tetsuya Kosaki
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Saki Hosokawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Go Kawamura
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Tatsuya Shigematsu
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Tatsunori Takahashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Yoshitaka Kawada
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Go Hiasa
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Tadakatsu Yamada
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Hiroshi Matsuoka
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Yukio Kazatani
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hideki Okayama.

Ethics declarations

Conflict of interest

The authors declare no conflicts of interest.

Funding

This study received no grant from any funding agency in the public, commercial, or not-for-profit sectors.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kinoshita, M., Okayama, H., Kosaki, T. et al. Favorable effects of early tolvaptan administration in very elderly patients after repeat hospitalizations for acute decompensated heart failure. Heart Vessels 33, 163–169 (2018). https://doi.org/10.1007/s00380-017-1048-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00380-017-1048-6

Keywords

Search

Navigation